The effects of low and high doses of sugammadex on kidney tissue in streptozotocin-induced diabetic rats.

BACKGROUND Sugammadex is primarily excreted via renal route. We investigated effects of low and high doses of sugammadex (16 mg/kg versus 96 mg/kg) on renal tissue samples of streptozotocin-induced diabetic rats. MATERIAL AND METHODS Twenty-four Wistar albino rats were divided into 4 groups. Group C (control - 0.9 % NaCl), Group DC (diabetes control; 55 mg/kg streptozotocin, IP, only), Group DR-16S (diabetes-rocuronium - 16 mg sugammadex, IV.) and Group DR-96S (diabetes- rocuronium - 96 mg sugammadex, IV). Renal tissue histopathological evaluation and antioxidant status (measurements of MDA levels and NO activities) were studied. RESULTS Significantly higher levels of all inflammation parameters (inflammation, degeneration/necrosis, tubular dilatation, tubular cell degeneration, dilatation in Bowman's space, tubular hyaline casts, and lymphocyte infiltration) were found in the 96 mg/kg sugammadex group. Higher MDA tissue levels and lower NO activity were found in the 96 mg/kg sugammadex group. DISCUSSION We can conclude that high-dose (96 mg/kg) sugammadex administration resulted in significant renal tissue damage in diabetic rats. As a consequence, low doses of sugammadex have to be preferred in diabetic patients (Tab. 2, Fig. 4, Ref. 26).

[1]  A. Lim,et al.  Diabetic nephropathy – complications and treatment , 2014, International journal of nephrology and renovascular disease.

[2]  M. C. V. D. Heuvel,et al.  Dialysability of sugammadex and its complex with rocuronium in intensive care patients with severe renal impairment. , 2012, British journal of anaesthesia.

[3]  R. Nelson,et al.  Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy , 2012, Kidney international.

[4]  R. Bedir,et al.  Reversal of Rocuronium-Induced Neuromuscular Block with Sugammadex and Resulting Histopathological Effects in Rat Kidneys , 2011, Renal failure.

[5]  J. Smeets,et al.  Sugammadex is cleared rapidly and primarily unchanged via renal excretion , 2011, Biopharmaceutics & drug disposition.

[6]  C. Lien.  A Randomized, Dose-Response Study of Sugammadex Given for the Reversal of Deep Rocuronium- or Vecuronium-Induced Neuromuscular Blockade Under Sevoflurane Anesthesia , 2011 .

[7]  M. W. van den Heuvel,et al.  Safety, tolerability and pharmacokinetics of sugammadex using single high doses (up to 96 mg/kg) in healthy adult subjects: a randomized, double-blind, crossover, placebo-controlled, single-centre study. , 2010, Clinical drug investigation.

[8]  J. Driessen,et al.  Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study. , 2010, British journal of anaesthesia.

[9]  R. Redfern,et al.  Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent , 2008, Drug design, development and therapy.

[10]  J. Driessen,et al.  Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function. , 2008, British journal of anaesthesia.

[11]  M. Welliver.  Update for nurse anesthetists--part 3--cyclodextrin introduction to anesthesia practice: form, function, and application. , 2007, AANA journal.

[12]  M. Caramori,et al.  Podocyte Detachment and Reduced Glomerular Capillary Endothelial Fenestration in Human Type 1 Diabetic Nephropathy , 2007, Diabetes.

[13]  J. A. Álvarez-Gómez,et al.  reversal of vecuronium-induced shallow neuromuscular blockade is significantly faster with sugammadex compared with neostigmine : 9ap7-8 , 2007 .

[14]  G. Cammu,et al.  reversal of pancuronium-induced block by the selective relaxant binding agent sugammadex : 9ap2-1 , 2007 .

[15]  J. Proost,et al.  Early Reversal of Profound Rocuronium-induced Neuromuscular Blockade by Sugammadex in a Randomized Multicenter Study: Efficacy, Safety, and Pharmacokinetics , 2007, Anesthesiology.

[16]  J. Stensballe,et al.  Reversal of Rocuronium-induced Neuromuscular Block by the Selective Relaxant Binding Agent Sugammadex: A Dose-finding and Safety Study , 2006, Anesthesiology.

[17]  Aruni Bhatnagar,et al.  Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. , 2005, Endocrine reviews.

[18]  A. Bom,et al.  Reversal of Neuromuscular Blockade and Simultaneous Increase in Plasma Rocuronium Concentration after the Intravenous Infusion of the Novel Reversal Agent Org 25969 , 2003, Anesthesiology.

[19]  Mark Bradley,et al.  A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. , 2002, Angewandte Chemie.

[20]  H. Ha,et al.  Reactive oxygen species as glucose signaling molecules in mesangial cells cultured under high glucose. , 2000, Kidney international. Supplement.

[21]  Masakazu Haneda,et al.  Mitogen-Activated Protein Kinase Cascade Is Activated in Glomeruli of Diabetic Rats and Glomerular Mesangial Cells Cultured Under High Glucose Conditions , 1997, Diabetes.

[22]  J. Nyengaard,et al.  Hyperglycemic Pseudohypoxia and Diabetic Complications , 1993, Diabetes.

[23]  N. Cortas,et al.  Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method. , 1990, Clinical chemistry.

[24]  H. Esterbauer,et al.  Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. , 1990, Methods in enzymology.